Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis

Gut

Volumn 60, Issue 3, 2011, Pages 387-396

  Beraza, Naiara ^a,b   Ofner Ziegenfuss, Lisa ^c   Ehedego, Haksier ^a   Boekschoten, Mark ^d   Bischoff, Stephan C ^e   Mueller, Michael ^d   Trauner, Michael ^c,f   Trautwein, Christian ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d WAGENINGEN UNIVERSITY   (Netherlands)

^e UNIVERSITY OF HOHENHEIM   (Germany)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; CHOLESTEROL 7ALPHA MONOOXYGENASE; CYCLIN D1; NOR URSODEOXYCHOLIC ACID; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; DRUG EFFECT; LIPID METABOLISM; LIPOGENESIS; LIVER CELL; LIVER CELL DAMAGE; LIVER HISTOLOGY; LIVER INJURY; LOW FAT DIET; MOUSE; MUTATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; CELL PROLIFERATION; DIET, FAT-RESTRICTED; DISEASE PROGRESSION; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; FATTY LIVER; HEPATOCYTES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPIDS; LIVER; LIVER CIRRHOSIS; MICE; MICE, KNOCKOUT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; URSODEOXYCHOLIC ACID;

EID: 79851511413     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.223834     Document Type: Article

References (29)

1. Beraza N, Ludde T, Assmus U, et al. Hepatocyte-specific IKK gamma/NEMO expression determines the degree of liver injury. Gastroenterology 2007;132:2504-17. (Pubitemid 46890863)
2. Beraza N, Malato Y, Sander LE, et al. Hepatocyte-specific NEMO deletion promotes NK/NKT cell- and TRAIL-dependent liver damage. J Exp Med 2009;206:1727-37.
3. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441:431-6. (Pubitemid 44050137)
4. Malato Y, Sander LE, Liedtke C, et al. Hepatocyte-specific inhibitor-of-kappaB-kinase deletion triggers the innate immune response and promotes earlier cell proliferation during liver regeneration. Hepatology 2008;47:2036-50. (Pubitemid 351945570)
5. Luedde T, Beraza N, Kotsikoris V, et al. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007;11:119-32. (Pubitemid 46209851)
6. Wagner M, Zollner G, Trauner M. New molecular insights into the mechanisms of cholestasis. J Hepatol 2009;51:565-80.
7. Thomas C, Pellicciari R, Pruzanski M, et al. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 2008;7:678-93.
8. Peet DJ, Janowski BA, Mangelsdorf DJ. The LXRs: a new class of oxysterol receptors. Curr Opin Genet Dev 1998;8:571-5. (Pubitemid 28477361)
9. Higuchi H, Gores GJ. Bile acid regulation of hepatic physiology: IV. Bile acids and death receptors. Am J Physiol Gastrointest Liver Physiol 2003;284:G734-8.
10. Higuchi H, Bronk SF, Takikawa Y, et al. The bile acid glycochenodeoxycholate induces trail-receptor 2/DR5 expression and apoptosis. J Biol Chem 2001;276:38610-18.
11. Higuchi H, Bronk SF, Taniai M, et al. Cholestasis increases tumor necrosis factor-related apoptotis-inducing ligand (TRAIL)-R2/DR5 expression and sensitizes the liver to TRAIL-mediated cytotoxicity. J Pharmacol Exp Ther 2002;303:461-7. (Pubitemid 35231214)
12. Higuchi H, Grambihler A, Canbay A, et al. Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1. J Biol Chem 2004;279:51-60. (Pubitemid 38044798)
13. Malhi H, Barreyro FJ, Isomoto H, et al. Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut 2007;56:1124-31. (Pubitemid 47123245)
14. Fickert P, Wagner M, Marschall HU, et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006;130:465-81. (Pubitemid 43202044)
15. Fickert P, Zollner G, Fuchsbichler A, et al. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002;123:1238-51.
16. Dai M, Wang P, Boyd AD, et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 2005;33:-175.
17. Qiao L, Shao J. SIRT1 regulates adiponectin gene expression through Foxo1-C/enhancer-binding protein alpha transcriptional complex. J Biol Chem 2006;281:39915-24. (Pubitemid 46041795)
18. Hirota K, Sakamaki J, Ishida J, et al. A combination of HNF-4 and Foxo1 is required for reciprocal transcriptional regulation of glucokinase and glucose-6-phosphatase genes in response to fasting and feeding. J Biol Chem 2008;283:32432-41.
19. Poupon R, Poupon RE. Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children. Pharmacol Ther 1995;66:1-15.
20. Heid HW, Moll R, Schwetlick I, et al. Adipophilin is a specific marker of lipid accumulation in diverse cell types and diseases. Cell Tissue Res 1998;294:309-21. (Pubitemid 28486407)
21. Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 2004;39:273-8. (Pubitemid 38222163)
22. Geier A, Wagner M, Dietrich CG, et al. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim Biophys Acta 2007;1773:283-308. (Pubitemid 46275063)
23. Houten SM, Watanabe M, Auwerx J. Endocrine functions of bile acids. EMBO J 2006;25:1419-25.
24. Beuers U, Boyer JL, Paumgartner G. Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications. Hepatology 1998;28:1449-53. (Pubitemid 28549111)
25. Ozcan U, Yilmaz E, Ozcan L, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006;313:1137-40. (Pubitemid 44300242)
26. Huang J, Iqbal J, Saha PK, et al. Molecular characterization of the role of orphan receptor small heterodimer partner in development of fatty liver. Hepatology 2007;46:147-57. (Pubitemid 47171931)
27. Keppler D, Konig J. Hepatic canalicular membrane 5: expression and localization of the conjugate export pump encoded by the MRP2 (cMRP/cMOAT) gene in liver. FASEB J 1997;11:509-16. (Pubitemid 27274424)
28. Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 2003;83:633-71. (Pubitemid 36378680)
29. Konig J, Nies AT, Cui Y, et al. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta 1999;1461:377-94.